
Safeguarding public health

Our Ref: IVD000670

Mr Peter Wei Lotus Global Co Ltd 15 Alexandra Road London NW8 0DP United Kingdom



Dear Mr Peter Wei,

IN VITRO DIAGNOSTIC MEDICAL DEVICES REGULATIONS 2002: REGULATION 44 Registration of manufacturers of *In-Vitro Diagnostic* Medical Devices and devices for Performance Evaluation

Thank you for informing the Competent Authority of the details of *Manufacturers* Name:- Shanghai Sinovae Tech Co Ltd located at Manufacturers Address:- 1207 No 99 Feng Pu Avenue Feng Xian District Shanghai 201400 China for whom you are acting as the authorised representative and for supplying the medical device information.

Your registration has been recorded based on your declaration that you have determined that the device(s) fall within the definition of "in vitro diagnostic medical device", and that you have classified it/them correctly taking into account the intended purpose(s) and mode(s) of action. In accepting your registration, I should make clear that the Competent Authority does not examine each individual notification and therefore cannot and does not necessarily endorse these determinations. Neither does this letter represent any form of accreditation or approval by the UK Competent Authority.

Your registration is based upon your declaration on the RG3 form and means that you should now be operating under the In Vitro Diagnostic Medical Devices Directive and the 2002 Regulations for the products you asked us to register, by fully complying with the essential requirements, CE marking those products or labelling them as such.

If you stop placing devices on the market or if you are not complying with the Regulations you should inform us as required by the Regulations. You should be aware that it is an offence to place on the market CE marked devices that do not comply with the Regulations.

The information you provided has been recorded against the reference number shown at the top of this letter, which we ask you to quote in all future correspondence and communications.

Please inform us of any changes to:

- the company information
- additional generic groups of devices or, for Annex II or Self-Test devices, additional devices
- discontinuation of a generic group of devices or, for Annex II or Self-Test devices, discontinuation of devices

Please use RG3, the Registration form, to tell us about any of these changes. A fee of £70 is payable for each change or set of changes notified.





For reagents, reagent products, calibration and control materials: group by common technological characteristics and/or analytes

New products:

Urine Single Test Strips (incl. tablets)
Urine Multi-constituent Test Strips
Other Specific Proteins Rapid Tests
Other Tumour Marker Rapid Tests
FSH - Rapid Test
HCG - Rapid Test
CH Hardware + accessories + consumables + software
LH - Rapid Test

Amphetamines Group - Rapid Test Amphetamines - Rapid Test Barbiturates - Rapid Test Benzodiazepines - Rapid Test Cannabinoids - Rapid Test

Cocaine + Cocaine Metabolites - Rapid Test

Methadone - Rapid Test Opiates - Rapid Test Phencyclidine - Rapid Test

Tricyclic Antidepressants - Rapid Test

Multiple Drugs of Abuse/Toxicology Rapid Tests
Other Drugs of Abuse/Toxicology Rapid Tests

C-Reactive Protein - Rapid Test

CK - MB / Myoglobin - Rapid Test

Myoglobin - Rapid Test Troponin I/T - Rapid Test

BNP / proBNP - Rapid Test (including other Natriuric Peptides)

Multiple Cardiac Markers

D-Dimer Rapid Test H. Pylori - Rapid Test

Strep A - Rapid Test

Syphilis - Rapid Test

Other Bacteriology Rapid Tests Other Hepatitis Viruses Rapid Tests

Plasmodium (Malaria) - Rapid Test

Mononucleosis - Rapid Test

Influenza A and /or B

Dengue - Rapid Test

Other Other Virology Rapid Tests

For performance evaluation:

None

Neither:

None



For other IVDs, group by appropriate indications

New products:

None

For performance evaluation:

None

Neither:

None

Part 6: IVDs which are Annex II or self-test devices

For reagents, reagent products, calibration and control materials: group by common technological characteristics and/or analytes

New products:

None

For performance evaluation:

None

Neither:

None

For other IVDs, group by appropriate indications

New products:

None

For performance evaluation:

None

Neither:

None

If you have any queries regarding your registration, please do not hesitate to contact us.

Yours sincerely

Barbara Clarke

Regulatory Affairs Administrator Email from barbara.clarke@mhra.gsi.gov.uk